EP4481047A3 - Biologisch abbaubare lipide zur freisetzung von wirkstoffen - Google Patents
Biologisch abbaubare lipide zur freisetzung von wirkstoffen Download PDFInfo
- Publication number
- EP4481047A3 EP4481047A3 EP24207850.9A EP24207850A EP4481047A3 EP 4481047 A3 EP4481047 A3 EP 4481047A3 EP 24207850 A EP24207850 A EP 24207850A EP 4481047 A3 EP4481047 A3 EP 4481047A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- lipid
- cationic
- delivery
- active agents
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/62—Quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35114610P | 2010-06-03 | 2010-06-03 | |
| US201161489197P | 2011-05-23 | 2011-05-23 | |
| EP17000656.3A EP3254672B1 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| EP11726579.3A EP2575764B1 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von aktiven verbindungen |
| PCT/US2011/039164 WO2011153493A2 (en) | 2010-06-03 | 2011-06-03 | Biodegradable lipids for the delivery of active agents |
Related Parent Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17000656.3A Division EP3254672B1 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| EP17000656.3A Division-Into EP3254672B1 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| EP11726579.3A Division EP2575764B1 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von aktiven verbindungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4481047A2 EP4481047A2 (de) | 2024-12-25 |
| EP4481047A3 true EP4481047A3 (de) | 2025-04-16 |
Family
ID=45067325
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17000656.3A Active EP3254672B1 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| EP11726579.3A Active EP2575764B1 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von aktiven verbindungen |
| EP24207850.9A Withdrawn EP4481047A3 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP17000656.3A Active EP3254672B1 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| EP11726579.3A Active EP2575764B1 (de) | 2010-06-03 | 2011-06-03 | Biologisch abbaubare lipide zur freisetzung von aktiven verbindungen |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9012498B2 (de) |
| EP (3) | EP3254672B1 (de) |
| JP (3) | JP5893611B2 (de) |
| KR (2) | KR101967411B1 (de) |
| CN (1) | CN103096875B (de) |
| AU (6) | AU2011261247B2 (de) |
| CA (1) | CA2800401C (de) |
| DK (2) | DK2575764T3 (de) |
| ES (2) | ES3053320T3 (de) |
| IL (3) | IL300109A (de) |
| MX (1) | MX341332B (de) |
| NZ (1) | NZ605079A (de) |
| SG (1) | SG186085A1 (de) |
| WO (1) | WO2011153493A2 (de) |
Families Citing this family (305)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110045473A1 (en) * | 2008-01-02 | 2011-02-24 | De Fougerolles Antonin | Liver screening method |
| PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| CA2800401C (en) * | 2010-06-03 | 2020-09-15 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| CN103153347A (zh) * | 2010-10-21 | 2013-06-12 | 默沙东公司 | 用于寡核苷酸递送的新型低分子量阳离子脂质 |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| ES3065854T3 (en) | 2011-12-07 | 2026-05-08 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| US9463247B2 (en) | 2011-12-07 | 2016-10-11 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| WO2013116126A1 (en) * | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9402816B2 (en) | 2012-04-19 | 2016-08-02 | Sima Therapeutics, Inc. | Diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| US9415109B2 (en) | 2012-07-06 | 2016-08-16 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| KR20150090072A (ko) | 2012-10-23 | 2015-08-05 | 카리스 라이프 사이언스 스위스 홀딩스 게엠베하 | 압타머 및 이의 용도 |
| EP2929035A1 (de) * | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Lipidnanopartikel zur freisetzung von mrna |
| US9687448B2 (en) | 2012-12-07 | 2017-06-27 | Alnylam Pharmaceuticals, Inc. | Nucleic acid lipid particle formulations |
| EP2935628B1 (de) | 2012-12-19 | 2018-03-21 | Caris Life Sciences Switzerland Holdings GmbH | Zusammensetzungen und verfahren für aptamer-screening |
| ES2981185T3 (es) | 2013-03-14 | 2024-10-07 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
| EP2968586B1 (de) | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Cftr-mrna-zusammensetzungen und zugehörige verfahren sowie verwendungen |
| MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
| US11224642B2 (en) | 2013-10-22 | 2022-01-18 | Translate Bio, Inc. | MRNA therapy for argininosuccinate synthetase deficiency |
| NZ720174A (en) | 2013-11-18 | 2018-11-30 | Arcturus Therapeutics Inc | Ionizable cationic lipid for rna delivery |
| US9365610B2 (en) | 2013-11-18 | 2016-06-14 | Arcturus Therapeutics, Inc. | Asymmetric ionizable cationic lipid for RNA delivery |
| EP3082760A1 (de) | 2013-12-19 | 2016-10-26 | Novartis AG | Leptin-mrna-zusammensetzungen und -formulierungen |
| JP6571679B2 (ja) | 2014-04-25 | 2019-09-04 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| IL316479A (en) | 2014-06-25 | 2024-12-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| KR101882634B1 (ko) | 2014-08-07 | 2018-07-26 | 다케다 야쿠힝 고교 가부시키가이샤 | 양이온성 지질 |
| WO2016027699A1 (ja) * | 2014-08-18 | 2016-02-25 | 日油株式会社 | 核酸送達のためのカチオン性脂質 |
| EP3234141A4 (de) | 2014-12-18 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Reversir-tm-verbindungen |
| EP3239132B1 (de) * | 2014-12-26 | 2019-03-06 | Eisai R&D Management Co., Ltd. | Kationisches lipid |
| US10385030B2 (en) * | 2015-01-30 | 2019-08-20 | Nof Corporation | Cationic lipid |
| JP2018526321A (ja) | 2015-04-27 | 2018-09-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ |
| HUE067372T2 (hu) * | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| US20170050945A1 (en) * | 2015-07-24 | 2017-02-23 | Insmed Incorporated | Compositions and methods for the treatment of sarcoidosis |
| US11564893B2 (en) * | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| CN108271360B (zh) * | 2015-09-14 | 2023-01-24 | 得克萨斯州大学系统董事会 | 亲脂阳离子树枝状聚合物及其用途 |
| RS63986B1 (sr) | 2015-10-28 | 2023-03-31 | Acuitas Therapeutics Inc | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| WO2017222016A1 (ja) | 2016-06-24 | 2017-12-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | カチオン性脂質 |
| CA3025812A1 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| EP4714454A2 (de) | 2016-10-26 | 2026-03-25 | Acuitas Therapeutics Inc. | Lipidnanopartikelformulierungen |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| EP3808380A1 (de) | 2016-12-08 | 2021-04-21 | CureVac AG | Rna zur behandlung oder prophylaxe einer lebererkrankung |
| US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US10383952B2 (en) | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
| US11464847B2 (en) | 2016-12-23 | 2022-10-11 | Curevac Ag | Lassa virus vaccine |
| BR112019014314A2 (pt) | 2017-01-11 | 2020-02-18 | The Trustees Of The University Of Pennsylvania | Composição, e, método de indução de uma resposta imune adaptativa contra vírus zika. |
| AU2018224326B2 (en) | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
| MA47800A (fr) | 2017-03-17 | 2020-01-22 | Univ Newcastle | Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire |
| US20200085944A1 (en) | 2017-03-17 | 2020-03-19 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| CN110914433A (zh) | 2017-03-24 | 2020-03-24 | 库尔维科公司 | 编码crispr相关蛋白质的核酸及其用途 |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| WO2018191719A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipid delivery of therapeutic agents to adipose tissue |
| ES2981244T3 (es) | 2017-04-28 | 2024-10-07 | Acuitas Therapeutics Inc | Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| US11377643B2 (en) | 2017-05-31 | 2022-07-05 | Ultragenyx Pharmaceutical Inc. | Therapeutics for glycogen storage disease type III |
| WO2018222890A1 (en) | 2017-05-31 | 2018-12-06 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency rna therapeutics |
| US11939600B2 (en) | 2017-05-31 | 2024-03-26 | Arcturus Therapeutics, Inc. | Compositions and methods for treating phenylketonuria |
| BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
| EP3662913A4 (de) | 2017-08-04 | 2021-06-30 | Kyowa Kirin Co., Ltd. | Nukleinsäurehaltige lipidnanopartikel |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP4501322A3 (de) | 2017-08-17 | 2025-04-16 | Acuitas Therapeutics, Inc. | Lipide zur verwendung in lipidnanopartikelformulierungen |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP3673069A1 (de) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyaviren-vakzin |
| JP6826014B2 (ja) | 2017-09-13 | 2021-02-03 | 株式会社東芝 | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット |
| SG11202002186VA (en) | 2017-10-19 | 2020-05-28 | Curevac Ag | Novel artificial nucleic acid molecules |
| WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
| US11692002B2 (en) | 2017-11-08 | 2023-07-04 | CureVac SE | RNA sequence adaptation |
| AU2018367909B2 (en) | 2017-11-17 | 2022-03-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
| EP3723796A1 (de) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus-impfstoff |
| MX2020006843A (es) | 2017-12-27 | 2020-09-03 | Takeda Pharmaceuticals Co | Nanoparticula de lipido que contiene acido nucleico y uso de la misma. |
| EP3733647B1 (de) | 2017-12-27 | 2022-06-15 | Eisai R&D Management Co., Ltd. | Kationisches lipid |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| DE202019006199U1 (de) | 2018-04-17 | 2026-01-12 | CureVac SE | Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung |
| WO2019232095A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Vitamin cationic lipids |
| BR112020025995A2 (pt) | 2018-06-18 | 2021-03-23 | Research Institute At Nationwide Children's Hospital | administração de microdistrofina músculo-específica por vetor de vírus adeno-associado para tratar a distrofia muscular |
| US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| EP3842412B1 (de) | 2018-08-21 | 2024-04-24 | Kabushiki Kaisha Toshiba | Biologisch abbaubare lipide zur freisetzung von wirkstoffen in tumorzellen umfassend zwei oder mehrere tertiäre aminogruppen |
| CN118421617A (zh) | 2018-08-24 | 2024-08-02 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
| WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| EP3860561B1 (de) * | 2018-10-01 | 2023-06-21 | Alnylam Pharmaceuticals, Inc. | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| US12583816B2 (en) | 2018-10-18 | 2026-03-24 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| CN119876276A (zh) | 2018-10-18 | 2025-04-25 | 武田药品工业株式会社 | T细胞的活化/增殖方法 |
| EP3883592A1 (de) | 2018-11-21 | 2021-09-29 | Translate Bio, Inc. | Behandlung von zystischer fibrose durch verabreichung von vernebelter mrna, die cftr codiert |
| KR20210108969A (ko) * | 2018-12-05 | 2021-09-03 | 인텔리아 테라퓨틱스, 인크. | 변형된 아민 지질 |
| PL3891274T3 (pl) | 2018-12-06 | 2024-03-25 | Arcturus Therapeutics, Inc. | Kompozycje i sposoby leczenia niedoboru transkarbamylazy ornityny |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| CN113453707A (zh) | 2018-12-21 | 2021-09-28 | 库瑞瓦格股份公司 | 用于疟疾疫苗的rna |
| JP7523449B2 (ja) | 2019-01-11 | 2024-07-26 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| EP4491229A3 (de) | 2019-02-08 | 2025-05-14 | CureVac SE | Codierung von in den suprachoroidalen raum bei der behandlung von augenerkrankungen verabreichter rna |
| US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
| EP3986452A1 (de) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus-mrna-impfstoff |
| JP7600208B2 (ja) | 2019-07-29 | 2024-12-16 | ジョージア テック リサーチ コーポレイション | 拘束された脂質を含むナノ材料およびその使用 |
| JP2022544412A (ja) | 2019-08-14 | 2022-10-18 | キュアバック アーゲー | 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物 |
| ES2918001B2 (es) | 2019-08-14 | 2026-05-13 | Acuitas Therapeutics Inc | Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos |
| WO2021055609A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| CN114901360A (zh) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | 用于递送核酸的新型脂质纳米颗粒 |
| WO2021141969A1 (en) | 2020-01-09 | 2021-07-15 | Guide Therapeutics, Inc. | Nanomaterials |
| EP3886897A1 (de) | 2020-02-04 | 2021-10-06 | CureVac AG | Coronavirusimpfstoff |
| WO2021178510A1 (en) | 2020-03-03 | 2021-09-10 | Arcturus Therapeutics, Inc. | Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
| CA3171231A1 (en) | 2020-03-09 | 2021-09-16 | Sean Michael Sullivan | Compositions and methods for inducing immune responses |
| IL296781A (en) | 2020-03-30 | 2022-11-01 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| CA3176844A1 (en) | 2020-05-01 | 2021-11-04 | Carlos G. PEREZ-GARCIA | Nucleic acids and methods of treatment for cystic fibrosis |
| TW202206097A (zh) | 2020-05-20 | 2022-02-16 | 美商旗艦先鋒創新有限責任公司 | 冠狀病毒抗原組成物及其用途 |
| EP4153223A1 (de) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Immunogene zusammensetzungen und verwendungen davon |
| IL298539A (en) | 2020-05-29 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Trem compositions and methods relating thereto |
| CA3182026A1 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| CN116322758A (zh) | 2020-05-29 | 2023-06-23 | 库尔维科欧洲股份公司 | 基于核酸的组合疫苗 |
| BR112022025586A2 (pt) | 2020-06-15 | 2023-03-07 | Res Inst Nationwide Childrens Hospital | Liberação de vetor de vírus adenoassociado para distrofias musculares |
| WO2025056938A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| CA3188801A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
| JP7798855B2 (ja) | 2020-07-16 | 2026-01-14 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子に使用するためのカチオン性脂質 |
| EP4172194A1 (de) | 2020-07-31 | 2023-05-03 | CureVac SE | Nukleinsäurecodierte antikörpermischungen |
| CN116171150A (zh) | 2020-08-14 | 2023-05-26 | 阿克丘勒斯治疗公司 | 冻干脂质纳米颗粒的方法 |
| CA3170743A1 (en) | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
| EP4208196A1 (de) | 2020-09-03 | 2023-07-12 | Flagship Pioneering Innovations VI, LLC | Immunogene zusammensetzungen und verwendungen davon |
| EP4211247A4 (de) | 2020-09-13 | 2024-11-13 | Arcturus Therapeutics, Inc. | Lipidnanopartikelverkapselung von grosser rna |
| US20240299309A1 (en) | 2020-12-22 | 2024-09-12 | CureVac SE | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| BR112023012377A2 (pt) | 2020-12-23 | 2023-10-24 | Flagship Pioneering Innovations Vi Llc | Composições de trems modificadas e usos das mesmas |
| WO2022146654A1 (en) | 2020-12-28 | 2022-07-07 | Janssen Pharmaceuticals, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
| MX2023008328A (es) | 2021-01-20 | 2023-08-15 | Beam Therapeutics Inc | Nanomateriales que comprenden una caracteristica biodegradable. |
| EP4087938A2 (de) | 2021-01-27 | 2022-11-16 | CureVac AG | Verfahren zur verringerung der immunstimulatorischen eigenschaften von in vitro transkribierter rna |
| US20240180954A1 (en) | 2021-02-04 | 2024-06-06 | Shionogi & Co., Ltd. | Cationic lipid |
| CN117098558A (zh) * | 2021-02-09 | 2023-11-21 | 塞瑞纳治疗公司 | 聚噁唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物 |
| MX2023011400A (es) | 2021-03-26 | 2023-10-09 | Glaxosmithkline Biologicals Sa | Composiciones inmunogenicas. |
| WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| WO2022215036A1 (en) | 2021-04-08 | 2022-10-13 | Vaxthera Sas | Coronavirus vaccine comprising a mosaic protein |
| CN117327270A (zh) * | 2021-04-08 | 2024-01-02 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| CN115197079A (zh) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| EP4321524B1 (de) | 2021-04-09 | 2025-12-10 | Sogo Pharmaceutical Co., Ltd. | Lipid und zusammensetzung |
| WO2022226008A2 (en) * | 2021-04-20 | 2022-10-27 | Generation Bio Co. | Cationic lipids and compositions thereof |
| EP4334446A1 (de) | 2021-05-03 | 2024-03-13 | CureVac SE | Verbesserte nukleinsäuresequenz für zelltypspezifische expression |
| CN115385820B (zh) * | 2021-05-09 | 2025-04-29 | 英维沃生物科技(苏州)有限公司 | 阳离子脂质及其应用 |
| EP4377457A1 (de) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Trem-zusammensetzungen und verwendungen davon |
| US20240342206A1 (en) | 2021-07-30 | 2024-10-17 | CureVac SE | mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES |
| WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
| CN117940158A (zh) | 2021-09-03 | 2024-04-26 | 库瑞瓦格欧洲公司 | 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒 |
| IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| TW202328067A (zh) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | 環狀脂質及其使用方法 |
| EP4402121A1 (de) | 2021-09-14 | 2024-07-24 | Renagade Therapeutics Management Inc. | Acyclische lipide und verfahren zur verwendung davon |
| DK4271818T3 (da) | 2021-09-17 | 2024-11-04 | Flagship Pioneering Innovations Vi Llc | Sammensætninger og fremgangsmåder til fremstilling af cirkulære polyribonukleotider |
| US20240417714A1 (en) | 2021-10-18 | 2024-12-19 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| EP4426832A1 (de) | 2021-11-03 | 2024-09-11 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Genaue genomeditierung mit retrons |
| JP2024542188A (ja) | 2021-11-16 | 2024-11-13 | セイル バイオメディシンズ インコーポレイテッド | 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法 |
| KR20240128683A (ko) | 2021-11-22 | 2024-08-26 | 세일 바이오메디슨스, 인크. | 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법 |
| CA3238370A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
| CN118900845A (zh) | 2021-11-24 | 2024-11-05 | 旗舰创业创新六公司 | 冠状病毒免疫原组合物及其用途 |
| IL312965A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and their uses |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| MX2024007307A (es) | 2021-12-17 | 2024-08-06 | Flagship Pioneering Innovations Vi Llc | Métodos de enriquecimiento de arn circular en condiciones desnaturalizantes. |
| EP4452935A1 (de) * | 2021-12-20 | 2024-10-30 | Beam Therapeutics Inc. | Ionisierbare aminlipide und lipidnanopartikel |
| AU2022417517A1 (en) | 2021-12-22 | 2024-06-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| MX2024007870A (es) | 2021-12-23 | 2024-08-15 | Flagship Pioneering Innovations Vi Llc | Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos. |
| CA3243054A1 (en) | 2021-12-23 | 2025-04-08 | Renagade Therapeutics Management Inc. | Constrained Lipids and Associated Utilization Processes |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
| EP4469063A1 (de) | 2022-01-27 | 2024-12-04 | BioNTech SE | Pharmazeutische zusammensetzungen zur abgabe von herpes-simplex-virus-antigenen und zugehörige verfahren |
| CN114409554A (zh) * | 2022-01-27 | 2022-04-29 | 英维沃生物科技(苏州)有限公司 | 一种新型阳离子脂质化合物及其组合物和用途 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| EP4499607A1 (de) | 2022-03-25 | 2025-02-05 | Sail Biomedicines, Inc. | Neue ionisierbare lipide und lipidnanopartikel und verfahren zur verwendung davon |
| CN116354836A (zh) * | 2022-03-25 | 2023-06-30 | 深圳市新合生物医疗科技有限公司 | 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统 |
| WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
| WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| US20250295687A1 (en) | 2022-05-09 | 2025-09-25 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| TW202409283A (zh) | 2022-05-13 | 2024-03-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 雙股ｄｎａ組合物及相關方法 |
| WO2023218431A1 (en) | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
| WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
| WO2023230295A1 (en) | 2022-05-25 | 2023-11-30 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| CN119562807A (zh) | 2022-05-30 | 2025-03-04 | 生物技术公司 | 用于递送核酸的复合物 |
| CN117263818B (zh) * | 2022-06-14 | 2026-05-08 | 杭州高田生物医药有限公司 | 阳离子脂质化合物及其制备方法和应用 |
| WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| AU2023311822A1 (en) | 2022-07-20 | 2025-01-09 | Beam Therapeutics Inc. | Nanomaterials comprising triols |
| CA3263437A1 (en) | 2022-07-29 | 2024-02-01 | Fujifilm Corporation | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE SIGNAL REGULATOR ALPHA PROTEIN (SIRPα) GENE |
| AU2023320333A1 (en) | 2022-08-01 | 2025-01-16 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
| EP4581012A2 (de) | 2022-08-31 | 2025-07-09 | Sail Biomedicines, Inc. | Neue ionisierbare lipide und lipidnanopartikel und verfahren zur verwendung davon |
| JPWO2024053648A1 (de) | 2022-09-06 | 2024-03-14 | ||
| CN115197431B (zh) * | 2022-09-15 | 2022-11-29 | 清华大学 | 脂质偶联完全可降解水溶性聚合物的合成及应用 |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| CN120225219A (zh) | 2022-09-23 | 2025-06-27 | 生物技术欧洲股份公司 | 用于递送肝期抗原的组合物及相关方法 |
| AU2023347390A1 (en) | 2022-09-23 | 2025-04-10 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
| CA3267272A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | FLU VIRUS VACCINES |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| AU2023357320A1 (en) | 2022-10-06 | 2025-04-17 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| EP4608442A1 (de) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Impfstoff auf nukleinsäurebasis |
| EP4612296A1 (de) | 2022-10-31 | 2025-09-10 | Flagship Pioneering Innovations VI, LLC | Zusammensetzungen und verfahren zur reinigung von polyribonukleotiden |
| TW202434728A (zh) | 2022-11-08 | 2024-09-01 | 美商旗艦先鋒創新有限責任公司 | 用於產生環狀多核糖核苷酸的組成物和方法 |
| WO2024121814A1 (en) | 2022-12-09 | 2024-06-13 | Takeda Pharmaceutical Company Limited | Modified immunomodulators |
| EP4385523A1 (de) | 2022-12-14 | 2024-06-19 | Beijing Jitai Pharmaceutical Technology Co., Ltd. | Topische injektionsformulierungen auf lipidbasis |
| WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
| KR20250137590A (ko) | 2022-12-22 | 2025-09-18 | 나노베이션 테라퓨틱스 인크. | 핵산 및 다른 치료제의 전달을 위한 황-함유 이온화 가능한 지질 |
| EP4642797A1 (de) | 2022-12-28 | 2025-11-05 | BioNTech SE | Gegen hiv gerichtete rna-zusammensetzungen |
| WO2024151673A2 (en) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Recombinant nucleic acid molecules and their use in wound healing |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| TW202438673A (zh) | 2023-01-09 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 疫苗及相關方法 |
| WO2024151685A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| EP4658239A1 (de) | 2023-02-03 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Rna-formulierung |
| WO2024167885A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
| AU2024217843A1 (en) | 2023-02-09 | 2025-07-31 | Alnylam Pharmaceuticals, Inc. | Reversir molecules and methods of use thereof |
| EP4665736A2 (de) | 2023-02-13 | 2025-12-24 | Flagship Pioneering Innovations VII, LLC | Spaltbare linker enthaltende ionisierbare lipide und lipidträger für therapeutische zusammensetzungen |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| JP2026507514A (ja) | 2023-02-17 | 2026-03-04 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | 修飾されたシトシンを含むｄｎａ組成物 |
| AU2024222598A1 (en) | 2023-02-17 | 2025-07-31 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified uracil |
| JP2026509258A (ja) | 2023-03-08 | 2026-03-17 | キュアバック エスイー | 核酸送達のための新規な脂質ナノ粒子製剤 |
| WO2024192422A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| AU2024235803A1 (en) | 2023-03-15 | 2025-09-25 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
| EP4687990A1 (de) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Verfahren zur synthese gezielter lipidnanopartikel und verwendungen davon |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| AR132276A1 (es) | 2023-04-07 | 2025-06-11 | Takeda Pharmaceuticals Co | Complejo de conjugación |
| JP2026514004A (ja) | 2023-04-12 | 2026-05-01 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 修飾されたｔｒｅｍ、組成物及びその関連方法 |
| EP4695391A1 (de) | 2023-04-12 | 2026-02-18 | Flagship Pioneering Innovations VI, LLC | Trems zur verwendung bei der korrektur von fehlmessungsmutationen |
| CR20250492A (es) * | 2023-04-12 | 2025-12-19 | Alnylam Pharmaceuticals Inc | Formulaciones para el suministro de oligonucleótidos |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| EP4701657A1 (de) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Impfstoffe gegen influenzavirus |
| WO2024228044A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
| AU2024266138A1 (en) | 2023-05-03 | 2025-11-13 | Manifold Biotechnologies, Inc. | Methods and compositions for high-throughput protein delivery, screening, and detection |
| AU2024265158A1 (en) | 2023-05-03 | 2025-11-06 | BioNTech SE | Optimized csp variants and related methods |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2024236361A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Compositions and methods for delivery of nucleic acids to cells |
| WO2024236504A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Sequences and methods for delivery of dna and rna |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| TW202517669A (zh) | 2023-07-05 | 2025-05-01 | 日商武田藥品工業股份有限公司 | 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體 |
| CN121532514A (zh) | 2023-07-07 | 2026-02-13 | 上海环码生物医药有限公司 | 用于季节性流感的环状rna疫苗及使用方法 |
| WO2025024324A1 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| IL325865A (en) | 2023-07-21 | 2026-03-01 | BioNTech SE | Compositions for administering Plasmodium antigens and related methods |
| WO2025024337A1 (en) | 2023-07-24 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| US20250092426A1 (en) | 2023-07-25 | 2025-03-20 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| WO2025027089A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thiolipids and uses thereof |
| CN121620589A (zh) | 2023-08-01 | 2026-03-06 | 法国居里学院 | 包含编码环gmp-amp合酶的核酸序列的纳米粒子 |
| WO2025026545A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thioplipids and uses thereof |
| CN121866336A (zh) | 2023-08-03 | 2026-04-14 | 百欧恩泰欧洲股份公司 | 靶向hiv的rna组合物 |
| WO2025030154A1 (en) | 2023-08-03 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods |
| CN121772938A (zh) | 2023-08-03 | 2026-03-31 | 百欧恩泰欧洲股份公司 | 用于递送单纯疱疹病毒抗原的药物组合物及相关方法 |
| WO2025027579A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025045142A1 (en) | 2023-08-29 | 2025-03-06 | Shanghai Circode Biomed Co., Ltd. | Circular rna encoding vegf polypeptides, formulations, and methods of uses |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025054556A1 (en) | 2023-09-07 | 2025-03-13 | BioNTech SE | Rna compositions for delivery of mpox antigens and related methods |
| AU2024343011A1 (en) | 2023-09-11 | 2026-03-26 | BioNTech SE | Rna compositions for delivery of incretin agents |
| TW202525266A (zh) | 2023-09-18 | 2025-07-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 可電離類脂質組成物及其治療用途 |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| AU2024357861A1 (en) | 2023-10-12 | 2026-04-23 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
| WO2025106670A1 (en) | 2023-11-14 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| TW202539697A (zh) | 2023-11-15 | 2025-10-16 | 德商拜恩技術股份公司 | 冠狀病毒疫苗 |
| TW202523695A (zh) | 2023-11-22 | 2025-06-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於治療非酒精性脂肪性肝病之方法及組成物 |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| CN120081892A (zh) * | 2023-12-01 | 2025-06-03 | 康希诺(上海)生物研发有限公司 | 一种可电离阳离子脂质化合物及其应用 |
| CN119143714B (zh) * | 2023-12-11 | 2025-06-10 | 仁景(苏州)生物科技有限公司 | 用于递送的脂质化合物和脂质纳米颗粒 |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025134066A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| TW202525287A (zh) | 2023-12-21 | 2025-07-01 | 德商拜恩技術運輸科技有限責任公司 | 可離子化脂質 |
| WO2025133105A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Compositions and methods |
| WO2025133115A1 (en) | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025149492A1 (en) | 2024-01-08 | 2025-07-17 | BioNTech SE | Rna encoding an immune inhibitory il-1 family member |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| TW202545974A (zh) | 2024-01-26 | 2025-12-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫受體抑制蛋白及相關方法 |
| WO2025171300A1 (en) * | 2024-02-07 | 2025-08-14 | General Therapeutics, Inc. | Lipids and lipid nanoparticles comprising the same |
| WO2025184508A1 (en) | 2024-03-01 | 2025-09-04 | Acuitas Therapeutics, Inc. | Materials and methods for encapsulating therapeutics in lipid nanoparticles |
| WO2025194019A1 (en) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025213131A1 (en) | 2024-04-05 | 2025-10-09 | BioNTech SE | Rna compositions for delivery of orthopox antigens and related methods |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2025240680A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025245188A2 (en) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Methods of treating liver steatosis and non-alcoholic fatty liver disease |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
| WO2025262460A1 (en) | 2024-06-21 | 2025-12-26 | BioNTech SE | Lipid compositions for nucleic acid delivery |
| US20260000702A1 (en) | 2024-06-26 | 2026-01-01 | Flagship Pioneering Innovations Vii, Llc | Therapeutic circular dna forms |
| WO2026015882A1 (en) | 2024-07-12 | 2026-01-15 | BioNTech SE | Hsv antigen fragments and related methods |
| WO2026018213A1 (en) | 2024-07-18 | 2026-01-22 | Vaxthera Sas | A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses |
| WO2026020171A2 (en) | 2024-07-19 | 2026-01-22 | Aera Therapeutics, Inc. | Chimeric antigen receptor constructs |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
| WO2026055543A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Modified dna compositions and related methods |
| WO2026055547A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| WO2026057626A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having multiple enzymatically active domains |
| WO2026057625A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having a chap domain with engineered active site |
| WO2026064313A1 (en) | 2024-09-17 | 2026-03-26 | Flagship Pioneering Innovations Vii, Llc | Rna compositions and related methods |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
| WO2026068864A1 (en) | 2024-09-30 | 2026-04-02 | BioNTech SE | Engineered ch1 and cl domains for the prevention of chain mispairing |
| WO2026085300A1 (en) | 2024-10-16 | 2026-04-23 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods |
| WO2026082899A2 (en) | 2024-10-16 | 2026-04-23 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2026093414A1 (en) | 2024-10-30 | 2026-05-07 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising membrane il-35 |
| WO2026096919A1 (en) | 2024-11-01 | 2026-05-07 | Sail Biomedicines, Inc. | Novel dipepetide core lipids, lipid carriers, and methods of using thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010054401A1 (en) * | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Novel lipids and compositions for the delivery of therapeutics |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| CH624011A5 (de) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| AU587989B2 (en) | 1984-10-16 | 1989-09-07 | Mitsubishi Chemical Corporation | DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins |
| ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| AU6522486A (en) | 1985-10-04 | 1987-04-24 | Biotechnology Research Partners Limited | Recombinant apolipoproteins and methods |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US4957773A (en) | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
| US5473039A (en) | 1989-08-18 | 1995-12-05 | The Scripps Research Institute | Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs |
| US5177189A (en) | 1989-08-18 | 1993-01-05 | The Scripps Research Institute | Polypeptide analogs of Apolipoprotein E |
| US5168045A (en) | 1989-08-18 | 1992-12-01 | The Scripps Research Institute | Diagnostic systems and methods using polypeptide analogs of apolipoprotein e |
| US5182364A (en) | 1990-02-26 | 1993-01-26 | The Scripps Research Institute | Polypeptide analogs of apolipoprotein E |
| US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE4013632A1 (de) * | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
| WO1993000443A1 (en) | 1991-06-26 | 1993-01-07 | Bio-Technology General Corp. | Purification of recombinant apolipoprotein e from bacteria |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| US6372886B1 (en) | 1992-06-23 | 2002-04-16 | Arch Development Corp. | Expression and purification of kringle domains of human apolipoprotein (a) in E. coli |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| AU6045094A (en) * | 1993-02-19 | 1994-09-14 | Nippon Shinyaku Co. Ltd. | Drug composition containing nucleic acid copolymer |
| US5532130A (en) | 1993-07-20 | 1996-07-02 | Dyad Pharmaceutical Corporation | Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides |
| CA2185450A1 (en) | 1994-03-22 | 1995-09-28 | Patrick Tso | Eating suppressant peptides |
| US5534499A (en) | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
| WO1996010585A1 (en) | 1994-09-30 | 1996-04-11 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| CA2222328C (en) | 1995-06-07 | 2012-01-10 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5672685A (en) | 1995-10-04 | 1997-09-30 | Duke University | Source of apolipoprotein E and method of isolating apolipoprotein E |
| JP3563505B2 (ja) * | 1995-10-16 | 2004-09-08 | 花王株式会社 | 新規な第４級アンモニウム塩及びその製造方法、並びにそれを含有する毛髪化粧料 |
| JPH09278726A (ja) * | 1996-04-11 | 1997-10-28 | Takeshi Imanishi | 新規リポソーム |
| JPH09301936A (ja) * | 1996-05-09 | 1997-11-25 | Kao Corp | 新規第４級アンモニウム塩、その製造方法及びそれを含有する柔軟仕上剤並びに毛髪化粧料 |
| WO1998051278A2 (en) | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US20030229037A1 (en) * | 2000-02-07 | 2003-12-11 | Ulrich Massing | Novel cationic amphiphiles |
| EP1519714B1 (de) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Verfahren und vorrichtung zur herstellung von liposomen |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| EP2476756A1 (de) * | 2005-06-15 | 2012-07-18 | Massachusetts Institute of Technology | Aminhaltige Lipide und ihre Verwendungen |
| CN103989633A (zh) | 2005-07-27 | 2014-08-20 | 普洛体维生物治疗公司 | 制造脂质体的系统和方法 |
| JP5325576B2 (ja) * | 2006-06-30 | 2013-10-23 | 北海道システム・サイエンス株式会社 | 核酸導入用組成物 |
| WO2008042973A2 (en) | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
| FR2909378B1 (fr) * | 2006-12-05 | 2012-01-13 | Biochimie Appliquee Soc | Ceramides ou pseudo-ceramides quaternises et les compositions cosmetiques en contenant |
| TW201002126A (en) * | 2007-12-21 | 2010-01-01 | Du Pont | Encapsulation assembly for electronic devices |
| JP5749494B2 (ja) * | 2008-01-02 | 2015-07-15 | テクミラ ファーマシューティカルズ コーポレイション | 核酸の送達のための改善された組成物および方法 |
| JP5777519B2 (ja) | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| US8722082B2 (en) | 2008-11-10 | 2014-05-13 | Tekmira Pharmaceuticals Corporation | Lipids and compositions for the delivery of therapeutics |
| CN102215820A (zh) * | 2008-11-17 | 2011-10-12 | 安龙制药公司 | 用于核酸输送系统的可释放融合脂质 |
| US20120101148A1 (en) | 2009-01-29 | 2012-04-26 | Alnylam Pharmaceuticals, Inc. | lipid formulation |
| SG176553A1 (en) | 2009-05-05 | 2012-01-30 | Muthiah Manoharan | Lipid compositions |
| CA2800401C (en) * | 2010-06-03 | 2020-09-15 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| ES3065854T3 (en) * | 2011-12-07 | 2026-05-08 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| JP6315156B2 (ja) | 2016-03-08 | 2018-04-25 | Dic株式会社 | 液晶組成物及びそれを使用した液晶表示素子 |
-
2011
- 2011-06-03 CA CA2800401A patent/CA2800401C/en active Active
- 2011-06-03 EP EP17000656.3A patent/EP3254672B1/de active Active
- 2011-06-03 US US13/153,200 patent/US9012498B2/en active Active
- 2011-06-03 SG SG2012087441A patent/SG186085A1/en unknown
- 2011-06-03 WO PCT/US2011/039164 patent/WO2011153493A2/en not_active Ceased
- 2011-06-03 DK DK11726579.3T patent/DK2575764T3/en active
- 2011-06-03 JP JP2013513394A patent/JP5893611B2/ja active Active
- 2011-06-03 KR KR1020137000092A patent/KR101967411B1/ko active Active
- 2011-06-03 IL IL300109A patent/IL300109A/en unknown
- 2011-06-03 DK DK17000656.3T patent/DK3254672T3/da active
- 2011-06-03 MX MX2012014079A patent/MX341332B/es active IP Right Grant
- 2011-06-03 ES ES17000656T patent/ES3053320T3/es active Active
- 2011-06-03 AU AU2011261247A patent/AU2011261247B2/en active Active
- 2011-06-03 CN CN201180037927.7A patent/CN103096875B/zh active Active
- 2011-06-03 KR KR1020197009607A patent/KR20190039347A/ko not_active Ceased
- 2011-06-03 EP EP11726579.3A patent/EP2575764B1/de active Active
- 2011-06-03 ES ES11726579.3T patent/ES2634087T3/es active Active
- 2011-06-03 NZ NZ605079A patent/NZ605079A/en unknown
- 2011-06-03 EP EP24207850.9A patent/EP4481047A3/de not_active Withdrawn
-
2012
- 2012-11-22 IL IL223207A patent/IL223207B/en active IP Right Grant
-
2015
- 2015-03-18 US US14/661,945 patent/US9682922B2/en active Active
-
2016
- 2016-02-23 JP JP2016031867A patent/JP6409011B2/ja active Active
- 2016-08-05 AU AU2016210739A patent/AU2016210739A1/en not_active Abandoned
-
2017
- 2017-05-15 US US15/595,646 patent/US10266484B2/en active Active
-
2018
- 2018-05-14 IL IL259334A patent/IL259334B2/en unknown
- 2018-05-15 AU AU2018203382A patent/AU2018203382A1/en not_active Abandoned
- 2018-09-21 JP JP2018177190A patent/JP2019011345A/ja active Pending
-
2020
- 2020-01-15 AU AU2020200286A patent/AU2020200286B2/en active Active
-
2022
- 2022-06-14 AU AU2022204146A patent/AU2022204146B2/en active Active
-
2024
- 2024-08-02 AU AU2024205466A patent/AU2024205466A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010054401A1 (en) * | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Novel lipids and compositions for the delivery of therapeutics |
Non-Patent Citations (2)
| Title |
|---|
| HONGTAO LV ET.AL.: "Toxicity of cationic lipids and cationic polymers in gene delivery", JOURNAL OF CONTROLLED RELEASE, vol. 114, 2006, pages 100 - 109, XP002664605 * |
| S. CHESNOY ET.AL.: "Structure and function of lipid-DNA complexes for gene delivery", ANNU. REV. BIOPHYS. BIOMOL. STRUC., vol. 29, 31 December 2000 (2000-12-31) - 2000, pages 27 - 47, XP002664604 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341332B (es) | Lipidos biodegradables para la administracion de agentes activos. | |
| EP4635481A3 (de) | Biologisch abbaubare lipide zur freisetzung von wirkstoffen | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| NZ622843A (en) | Improved lipid formulation | |
| WO2009149418A3 (en) | Compositions for the in vivo delivery of rnai agents | |
| WO2011141705A8 (en) | Novel cationic lipids and methods of use thereof | |
| WO2008105773A3 (en) | System for targeted delivery of therapeutic agents | |
| WO2011133925A3 (en) | Targeted and light-activated cytosolic drug delivery | |
| NZ700075A (en) | Trialkyl cationic lipids and methods of use thereof | |
| MX2019005287A (es) | Lipidos cationicos para suministro de acido nucleico y su preparacion. | |
| WO2011076807A3 (en) | Lipids, lipid compositions, and methods of using them | |
| WO2012103038A9 (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| HK1217085A1 (zh) | 包封在顆粒中的靶向綴合物及其製劑 | |
| WO2007137117A3 (en) | Aptamer-directed drug delivery | |
| WO2012170889A8 (en) | Cleavable lipids | |
| WO2013135359A8 (en) | Targeting aminoacid lipids | |
| WO2012054500A3 (en) | Compositions for drug administration | |
| EP4241767A3 (de) | Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika | |
| MX2023008180A (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
| WO2007110422A3 (en) | Whey protein vehicle for active agent delivery | |
| WO2011087548A3 (en) | Therapeutic compositions and methods for targeted delivery of active agents | |
| WO2014058179A3 (ko) | 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물 | |
| WO2012006169A3 (en) | Compositions and methods for enhancement of nucleic acid delivery | |
| IN2014MN01886A (de) | ||
| MX360315B (es) | Composiciones farmaceuticas que comprenden un inhibidor de aromatasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20241021 |
|
| AC | Divisional application: reference to earlier application |
Ref document number: 2575764 Country of ref document: EP Kind code of ref document: P Ref document number: 3254672 Country of ref document: EP Kind code of ref document: P |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C12N0015880000 Ipc: A61K0009100000 |
|
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Free format text: CASE NUMBER: APP_10088/2025 Effective date: 20250227 |
|
| AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/87 20060101ALI20250310BHEP Ipc: C07C 211/63 20060101ALI20250310BHEP Ipc: C07C 211/62 20060101ALI20250310BHEP Ipc: C07C 69/02 20060101ALI20250310BHEP Ipc: A61K 48/00 20060101ALI20250310BHEP Ipc: A61K 39/00 20060101ALI20250310BHEP Ipc: A61K 9/10 20060101AFI20250310BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20251017 |